[
  {
    "ts": null,
    "headline": "Will Moody's (MCO) Beat Estimates Again in Its Next Earnings Report?",
    "summary": "Moody's (MCO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
    "url": "https://finnhub.io/api/news?id=c636543804fb51f0cf2bb9f8932f855ade723a111a550bfe900409603fda117b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760717404,
      "headline": "Will Moody's (MCO) Beat Estimates Again in Its Next Earnings Report?",
      "id": 137127690,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MCO",
      "source": "Yahoo",
      "summary": "Moody's (MCO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
      "url": "https://finnhub.io/api/news?id=c636543804fb51f0cf2bb9f8932f855ade723a111a550bfe900409603fda117b"
    }
  },
  {
    "ts": null,
    "headline": "Moody’s upgraded ahead of Q3 on strong issuance boost",
    "summary": "Investing.com -- Raymond James upgraded Moody’s to Market Perform from Underperform ahead of the company’s third-quarter results on stronger issuance activity and reduced downside risk to its valuation multiple.",
    "url": "https://finnhub.io/api/news?id=69d8f72dc67b72f4869bf0223eaa6ffa80ea986f0d7a1aea888f7bb5b8b97a0d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760708880,
      "headline": "Moody’s upgraded ahead of Q3 on strong issuance boost",
      "id": 137125926,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MCO",
      "source": "Yahoo",
      "summary": "Investing.com -- Raymond James upgraded Moody’s to Market Perform from Underperform ahead of the company’s third-quarter results on stronger issuance activity and reduced downside risk to its valuation multiple.",
      "url": "https://finnhub.io/api/news?id=69d8f72dc67b72f4869bf0223eaa6ffa80ea986f0d7a1aea888f7bb5b8b97a0d"
    }
  },
  {
    "ts": null,
    "headline": "Insights Into Moody's (MCO) Q3: Wall Street Projections for Key Metrics",
    "summary": "Besides Wall Street's top-and-bottom-line estimates for Moody's (MCO), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.",
    "url": "https://finnhub.io/api/news?id=c26290231b8eaf20e9b8d47b008b0cc92b12b388cfb717fd9d4c80d389b9e943",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760706902,
      "headline": "Insights Into Moody's (MCO) Q3: Wall Street Projections for Key Metrics",
      "id": 137125927,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MCO",
      "source": "Yahoo",
      "summary": "Besides Wall Street's top-and-bottom-line estimates for Moody's (MCO), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.",
      "url": "https://finnhub.io/api/news?id=c26290231b8eaf20e9b8d47b008b0cc92b12b388cfb717fd9d4c80d389b9e943"
    }
  },
  {
    "ts": null,
    "headline": "Teva Vs. Viatris: Who Will Dominate In President Trump's America?",
    "summary": "Compare Teva vs. Viatris for long-term investment in the $613B generic drugs market.",
    "url": "https://finnhub.io/api/news?id=5c3fea24dca232640cf1a10a80af361e6c899218576f0694fd728539e8ced9b4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760703531,
      "headline": "Teva Vs. Viatris: Who Will Dominate In President Trump's America?",
      "id": 137126958,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1253774892/image_1253774892.jpg?io=getty-c-w1536",
      "related": "MCO",
      "source": "SeekingAlpha",
      "summary": "Compare Teva vs. Viatris for long-term investment in the $613B generic drugs market.",
      "url": "https://finnhub.io/api/news?id=5c3fea24dca232640cf1a10a80af361e6c899218576f0694fd728539e8ced9b4"
    }
  },
  {
    "ts": null,
    "headline": "Mizuho Maintains Moody's (MCO) Neutral Recommendation",
    "summary": "Mizuho Maintains Moody's (MCO) Neutral Recommendation",
    "url": "https://finnhub.io/api/news?id=dce1f87b2e06fb7209f6e68e7b6913f6f9131d3e14158a0f9746d471bc477caa",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760659623,
      "headline": "Mizuho Maintains Moody's (MCO) Neutral Recommendation",
      "id": 137119138,
      "image": "",
      "related": "MCO",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=dce1f87b2e06fb7209f6e68e7b6913f6f9131d3e14158a0f9746d471bc477caa"
    }
  },
  {
    "ts": null,
    "headline": "BMO Capital Maintains Moody's (MCO) Market Perform Recommendation",
    "summary": "BMO Capital Maintains Moody's (MCO) Market Perform Recommendation",
    "url": "https://finnhub.io/api/news?id=1ea0c65ff5a3243daff4250444d8b15d3899ff3dd2562fede5c861654c3a0097",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760659561,
      "headline": "BMO Capital Maintains Moody's (MCO) Market Perform Recommendation",
      "id": 137119159,
      "image": "",
      "related": "MCO",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=1ea0c65ff5a3243daff4250444d8b15d3899ff3dd2562fede5c861654c3a0097"
    }
  }
]